PMID- 32445760
OWN - NLM
STAT- MEDLINE
DCOM- 20200625
LR  - 20211204
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 255
DP  - 2020 Aug 15
TI  - Sulforaphane protects against skeletal muscle dysfunction in spontaneous type 2 
      diabetic db/db mice.
PG  - 117823
LID - S0024-3205(20)30572-5 [pii]
LID - 10.1016/j.lfs.2020.117823 [doi]
AB  - AIMS: Skeletal muscle diseases have become to be the most common complication in 
      patients with type 2 diabetic mellitus (T2DM). However, the effective therapies 
      against skeletal muscle diseases are not yet available. Sulforaphane (SFN) is an 
      organic isothiocyanate found in cruciferous plants. Our aim was to explore 
      whether SFN could attenuate the skeletal muscle diseases in spontaneous type 2 
      diabetic db/db mice. MATERIALS AND METHODS: The db/m and littermate db/db mice 
      were treated with SFN or dimethyl sulfoxide. The grip strength of mice was 
      measured by a grasping forcing machine. The electron transmission microscopy was 
      used to perform the skeletal muscle. The western blot was used to detect the 
      nuclear factor E2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) signal pathway 
      related proteins, and inflammatory and apoptotic associated proteins. The mRNA 
      levels of anti-inflammatory and anti-oxidative relative genes were detected by 
      RT-QPCR. KEY FINDINGS: We found that SFN could significantly increase the grip 
      strength of the db/db mice. The lean mass and gastrocnemius mass were increased 
      in the db/db mice after administration with SFN. Additionally, the db/db mice 
      restored the skeletal muscle fiber organization after SFN treatment. 
      Mechanistically, SFN could activate the Nrf2/HO-1 signal pathway, and 
      downregulate the expression of inflammatory and apoptotic associated proteins. 
      Furthermore, SFN could also regulate the mRNA levels of anti-inflammatory and 
      anti-oxidative related genes. SIGNIFICANCE: Our results demonstrated that SFN can 
      protect against skeletal muscle diseases in db/db type 2 diabetic mice and 
      provide a potential drug to prevent skeletal muscle dysfunction in T2DM patients.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Wang, Meili
AU  - Wang M
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Pu, Die
AU  - Pu D
AD  - Department of Geriatrics, The Second Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Zhao, Yuxing
AU  - Zhao Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Chen, Jinliang
AU  - Chen J
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Zhu, Shiyu
AU  - Zhu S
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Lu, Ankang
AU  - Lu A
AD  - Department of Geriatrics, The Second Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Liao, Zhilin
AU  - Liao Z
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Sun, Yue
AU  - Sun Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China.
FAU - Xiao, Qian
AU  - Xiao Q
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China. Electronic address: xiaoqian1956@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200520
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antioxidants)
RN  - 0 (Isothiocyanates)
RN  - 0 (Membrane Proteins)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Nfe2l2 protein, rat)
RN  - 0 (RNA, Messenger)
RN  - 0 (Sulfoxides)
RN  - EC 1.14.14.18 (Heme Oxygenase-1)
RN  - EC 1.14.14.18 (Hmox1 protein, mouse)
RN  - GA49J4310U (sulforaphane)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Diabetes Mellitus, Experimental/*complications/drug therapy
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy
MH  - Heme Oxygenase-1/metabolism
MH  - Isothiocyanates/*pharmacology
MH  - Male
MH  - Membrane Proteins/metabolism
MH  - Mice
MH  - Muscle, Skeletal/*drug effects/pathology
MH  - Muscular Diseases/etiology/*prevention & control
MH  - NF-E2-Related Factor 2/metabolism
MH  - RNA, Messenger/metabolism
MH  - Sulfoxides
OTO - NOTNLM
OT  - Nrf2/HO-1 signal pathway
OT  - Skeletal muscle
OT  - Sulforaphane
COIS- Declaration of competing interest All the authors declare that there are no 
      conflicts of interest.
EDAT- 2020/05/24 06:00
MHDA- 2020/06/26 06:00
CRDT- 2020/05/24 06:00
PHST- 2020/01/11 00:00 [received]
PHST- 2020/05/08 00:00 [revised]
PHST- 2020/05/18 00:00 [accepted]
PHST- 2020/05/24 06:00 [pubmed]
PHST- 2020/06/26 06:00 [medline]
PHST- 2020/05/24 06:00 [entrez]
AID - S0024-3205(20)30572-5 [pii]
AID - 10.1016/j.lfs.2020.117823 [doi]
PST - ppublish
SO  - Life Sci. 2020 Aug 15;255:117823. doi: 10.1016/j.lfs.2020.117823. Epub 2020 May 
      20.